Chinyere Ofonagoro, MD
Internal Medicine · New Windsor, NYNPI 1477518231
Payments from drug & device makers
Across 97 payments — averaging $22.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$303
- Novo Nordisk$299
- AstraZeneca$289
- AbbVie$208
- Organogenesis Inc.$127
- Lilly USA, LLC$110
- plus $863 from 23 others
What the payments were for
- Food & beverage$2,201100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 19 | $303 |
| Novo Nordisk | 12 | $299 |
| AstraZeneca | 11 | $289 |
| AbbVie | 8 | $208 |
| Organogenesis Inc. | 1 | $127 |
| Lilly USA, LLC | 7 | $110 |
| Gilead | 1 | $100 |
| GSK | 6 | $94 |
| Kvk-tech, Inc. | 1 | $92 |
| Pfizer | 4 | $92 |
| Advanced Oxygen Therapy Inc. | 3 | $64 |
| Paratek Pharmaceuticals, Inc. | 2 | $48 |
| Reprise Biomedical, Inc. | 3 | $43 |
| Boehringer Ingelheim | 2 | $38 |
| Bioventus LLC | 1 | $31 |
| Merck | 2 | $31 |
| Kerecis Limited | 1 | $24 |
| Bardy Diagnostics, Inc. | 2 | $24 |
| Dexcom, Inc. | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Abbott | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PURAPLY WOUND MATRIX$127
- AIRSUPRA$125
- Ozempic$125
- Descovy$100
How this compares
$2,201 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $114,033 |
| FarxigaDapagliflozin Propanediol | 64 | $65,897 |
| TrulicityDulaglutide | 43 | $41,155 |
| EliquisApixaban | 57 | $39,250 |
| MounjaroTirzepatide | 33 | $34,190 |
| SantylCollagenase Clostridium Hist. | 21 | $29,024 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 29 | $26,318 |
| JanuviaSitagliptin Phosphate | 14 | $21,161 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $19,580 |
| XareltoRivaroxaban | 21 | $18,669 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $14,196 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $7,534 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,734 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $5,739 |
| Levothyroxine Sodium | 133 | $3,635 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $299 | $114,03359 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $110 | $75,34576 claims |
| AstraZenecaFarxiga | $289 | $65,89764 claims |
| PfizerEliquis | $92 | $39,25057 claims |
| Smith+NephewSantyl | $303 | $29,02421 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $94 | $25,32046 claims |
| MerckJanuvia | $31 | $21,16114 claims |
| Johnson & JohnsonXarelto | $14 | $18,66921 claims |
| AbbVieNamzaric, Synthroid | $208 | $8,99826 claims |
| Boehringer IngelheimSpiriva Respimat | $38 | $6,73413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New Windsor
- Sashi MakamNew Windsor$6.2M
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.